133 related articles for article (PubMed ID: 36567618)
21. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
[TBL] [Abstract][Full Text] [Related]
22.
Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547390
[TBL] [Abstract][Full Text] [Related]
23. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
24. Clinical and biomarker predictors of side effects from tamoxifen.
Lorizio W; Wu AH; Beattie MS; Rugo H; Tchu S; Kerlikowske K; Ziv E
Breast Cancer Res Treat; 2012 Apr; 132(3):1107-18. PubMed ID: 22207277
[TBL] [Abstract][Full Text] [Related]
25. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
de Vries Schultink AHM; Huitema ADR; Beijnen JH
Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22.
Baxter SD; Teft WA; Choi YH; Winquist E; Kim RB
Breast Cancer Res Treat; 2014 Jun; 145(2):419-28. PubMed ID: 24744093
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
Souwer ETD; Sanchez-Spitman A; Moes DJAR; Gelderblom H; Swen JJ; Portielje JEA; Guchelaar HJ; van Gelder T
Breast Cancer Res Treat; 2023 Jun; 199(3):471-478. PubMed ID: 37067610
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
30. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
de Vries Schultink AH; Alexi X; van Werkhoven E; Madlensky L; Natarajan L; Flatt SW; Zwart W; Linn SC; Parker BA; Wu AH; Pierce JP; Huitema AD; Beijnen JH
Breast Cancer Res Treat; 2017 Feb; 161(3):567-574. PubMed ID: 28005246
[TBL] [Abstract][Full Text] [Related]
31. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.
Jager NG; Koornstra RH; Vincent AD; van Schaik RH; Huitema AD; Korse TM; Schellens JH; Linn SC; Beijnen JH
BMC Cancer; 2013 Dec; 13():612. PubMed ID: 24373320
[TBL] [Abstract][Full Text] [Related]
32. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
34. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
35. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
36. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
[TBL] [Abstract][Full Text] [Related]
37. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi AK; Karim H; Lafolie P; Pohanka A; Östervall J; Hatschek T; Vitols S
Ther Drug Monit; 2016 Apr; 38(2):239-45. PubMed ID: 26485084
[TBL] [Abstract][Full Text] [Related]
38. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Irvin WJ; Walko CM; Weck KE; Ibrahim JG; Chiu WK; Dees EC; Moore SG; Olajide OA; Graham ML; Canale ST; Raab RE; Corso SW; Peppercorn JM; Anderson SM; Friedman KJ; Ogburn ET; Desta Z; Flockhart DA; McLeod HL; Evans JP; Carey LA
J Clin Oncol; 2011 Aug; 29(24):3232-9. PubMed ID: 21768473
[TBL] [Abstract][Full Text] [Related]
39. Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry.
Ng ES; Kangarloo SB; Konno M; Paterson A; Magliocco AM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):475-84. PubMed ID: 24414550
[TBL] [Abstract][Full Text] [Related]
40. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]